PHR
HealthcarePhreesia, Inc. · Medical - Healthcare Information Services · $550M
What is Phreesia, Inc.?
Phreesia, Inc. is a healthcare technology company that provides a SaaS-based platform designed to streamline patient intake, payments, and engagement for healthcare providers across the United States and Canada.
Phreesia generates revenue by licensing its cloud-based platform to healthcare organizations, enabling them to automate patient registration, verify insurance, collect payments, and communicate with patients digitally. The platform also serves life sciences clients by delivering targeted health content to patients at the point of care. Providers access the platform through mobile devices, web dashboards, self-service tablets, and on-site kiosks, giving Phreesia a flexible deployment model across a wide range of practice sizes and specialties.
Phreesia was incorporated in 2019 and is headquartered in Wilmington, US.
- Patient intake automation via mobile, tablet, and kiosk modalities
- Integrated payment processing and cost estimation tools
- Insurance verification and revenue cycle management solutions
- Online appointment scheduling, reminders, and referral tracking
- Life sciences patient engagement and health campaign delivery
Is PHR a Good Stock to Buy?
UQS Score rates PHR as Good overall, reflecting a balanced profile with meaningful strengths and some areas of concern.
Phreesia's Growth and Quality pillars both register as Good, suggesting the business is expanding its footprint in healthcare SaaS while maintaining an acceptable operational foundation. The Risk pillar also comes in at Good, indicating the company's risk profile is manageable relative to peers in the small-cap healthcare technology space.
The Moat pillar is rated Weak, pointing to limited durable competitive advantages that could make it harder for Phreesia to fend off rivals over the long term. Valuation sits at Neutral, meaning the stock is neither obviously cheap nor clearly expensive at current levels.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PHR pay dividends?
No — Phreesia, Inc. does not currently pay a dividend.
Phreesia does not currently pay a dividend. As a growth-oriented healthcare SaaS company, it reinvests available capital into platform development, customer acquisition, and expanding its network of healthcare clients rather than returning cash to shareholders through distributions. Income-focused investors should factor this into their assessment.
When does PHR report earnings?
Phreesia reports earnings on a quarterly cadence, typical for US-listed equities.
Phreesia's recent quarters have reflected the dynamics of a growth-stage SaaS business — prioritizing network expansion and platform investment over near-term profitability. Revenue trends have generally moved in a positive direction, though the path to sustained profitability remains a key focus for investors tracking the company.
For the most recent quarter's results, visit Phreesia's investor relations page directly.
PHR Price History
-81.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Phreesia, Inc.?
Based on Phreesia, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PHR Long-term Outlook
Phreesia's fundamental outlook is shaped by its Good Growth pillar, which suggests the company continues to add healthcare clients and expand platform usage. The Good Risk rating indicates the business is not facing acute financial or operational stress. However, the Weak Moat pillar introduces uncertainty about whether Phreesia can sustain its growth trajectory against better-entrenched competitors. The Neutral Valuation label suggests the market has already priced in a reasonable growth scenario, leaving less room for upside surprise.
Growth drivers
- Continued adoption of digital patient intake across independent and health-system practices
- Expansion of life sciences revenue through targeted patient engagement at the point of care
- Cross-selling additional platform modules — scheduling, payments, clinical support — to existing clients
Key risks
- Weak competitive moat leaves Phreesia exposed to displacement by larger EHR vendors bundling similar features
- Sustained investment in growth may pressure profitability timelines if client acquisition slows
- Neutral valuation provides limited margin of safety if growth expectations are not met
PHR vs Peers
Phreesia operates in a competitive healthcare technology landscape alongside several other companies targeting provider workflow and patient engagement.
Vitalhub focuses on care coordination and patient flow software primarily for acute and mental health settings, whereas Phreesia targets outpatient intake and payments.
Nutex Health operates a hybrid healthcare services and technology model centered on micro-hospital facilities, a fundamentally different approach from Phreesia's pure SaaS platform.
HealthStream concentrates on workforce development and learning management for healthcare professionals, making it a complementary rather than direct competitor to Phreesia's patient-facing platform.
Frequently Asked Questions
What does Phreesia do?
Phreesia provides a SaaS-based platform that helps healthcare organizations manage patient intake, automate registration, verify insurance, collect payments, and communicate with patients. It also offers life sciences clients a channel to deliver relevant health content to patients at the point of care, across mobile, tablet, kiosk, and web-based interfaces.
Does PHR pay dividends?
No, Phreesia does not pay a dividend. The company reinvests capital into growing its platform and expanding its healthcare client base. Investors seeking regular income distributions should note that PHR is structured as a growth-oriented business at this stage.
When does PHR report earnings?
Phreesia reports financial results on a quarterly basis, consistent with standard US-listed company practice. For confirmed dates of upcoming earnings releases, check Phreesia's official investor relations page, as our data source does not carry forward-looking earnings calendar data.
Is PHR a good stock to buy?
UQS Score rates PHR as Good overall. The platform shows positive growth and a manageable risk profile, but the Weak Moat pillar raises questions about long-term competitive durability. Whether PHR fits your portfolio depends on your risk tolerance and investment horizon. View the full pillar breakdown on UQS Pro for a deeper assessment.
Is PHR overvalued?
The UQS Valuation pillar for PHR is rated Neutral, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. This means the current price appears to reflect a balanced market expectation, without a strong margin of safety or a significant premium above intrinsic value indicators.
How does PHR compare to its competitors?
Phreesia occupies a distinct niche focused on outpatient patient intake and payments, differentiating it from peers like HealthStream, which targets healthcare workforce learning, and Vitalhub, which serves acute care settings. Nutex Health operates a hybrid facility model that is structurally different from Phreesia's pure SaaS approach.
What is PHR's market cap bracket?
Phreesia is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large-cap or mega-cap healthcare technology peers.
Who founded Phreesia?
Phreesia was founded by Chaim Indig and Evan Roberts. The company has grown from a patient intake technology startup into a multi-module SaaS platform serving a broad range of healthcare providers across the United States and Canada.
Is PHR a long-term quality investment?
As a long-term quality indicator, UQS rates PHR as Good — reflecting positive growth dynamics and a manageable risk profile. However, the Weak Moat rating is a meaningful consideration for long-term holders, as durable competitive advantages are a key driver of sustained value creation over multi-year horizons.
What is the main competitive advantage of Phreesia?
Phreesia's platform advantage lies in its deep integration into the patient intake workflow, creating switching costs for healthcare clients who have embedded it into their registration and payment processes. That said, the UQS Moat pillar rates this advantage as Weak, indicating it may not be sufficiently durable to prevent competition from larger EHR vendors.
What sector does PHR belong to?
Phreesia operates in the Healthcare sector, specifically within healthcare technology and SaaS-based provider workflow software. It serves both healthcare services clients — such as physician practices and health systems — and life sciences companies seeking patient engagement channels.
Is PHR a growth stock or value stock?
Based on UQS pillar labels, PHR leans toward the growth category — its Growth pillar is rated Good, reflecting ongoing platform expansion. The Valuation pillar is Neutral, meaning it does not screen as a deep-value opportunity. This profile is typical of a growth-stage SaaS company reinvesting heavily to scale its client network.
Unlock Full PHR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓See how PHR ranks within the Healthcare sector
- ✓Compare PHR side-by-side with key competitors
- ✓Get the complete analyst-style quality breakdown
- ✓Track PHR score changes as new data is released
Pro Analysis
PHR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 24, 2026 | 47.4 | 34.5 | 39.0 | 60.1 | 52.3 | 61.3 | -0.1 |
| May 22, 2026 | 47.5 | 34.5 | 39.0 | 60.1 | 52.3 | 61.5 | 0.0 |
| May 21, 2026 | 47.5 | 34.5 | 39.0 | 60.1 | 52.3 | 61.9 | +0.1 |
| May 14, 2026 | 47.4 | 34.5 | 39.0 | 60.1 | 52.3 | 60.9 | +0.1 |
| May 12, 2026 | 47.3 | 34.5 | 39.0 | 60.1 | 52.3 | 60.1 | -9.9 |
| May 7, 2026 | 57.2 | 60.4 | 39.0 | 79.5 | 70.0 | 39.6 | +0.2 |
| May 3, 2026 | 57.0 | 60.4 | 39.0 | 79.5 | 70.0 | 38.6 | -0.1 |
| Apr 26, 2026 | 57.1 | 60.4 | 39.0 | 79.5 | 70.0 | 39.3 | -0.2 |
| Apr 19, 2026 | 57.3 | 60.4 | 39.0 | 79.5 | 70.0 | 40.7 | -0.5 |
| Apr 18, 2026 | 57.8 | 60.4 | 39.0 | 79.5 | 70.0 | 43.8 | -1.0 |
PHR — Pillar Breakdown
Quality
— 34.5/100 (25%)Phreesia, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 60.1/100 (20%)Phreesia, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 52.3/100 (15%)Phreesia, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 61.0/100 (15%)Phreesia, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 39/100 (25%)Phreesia, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PHR.
Score Composition
Financial Data
More Stock Analysis
How is the PHR UQS Score Calculated?
The UQS (Unified Quality Score) for Phreesia, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Phreesia, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Phreesia, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.